Through purpose-driven science, empowering medicines, and transformative advocacy we seek to improve the lives of millions.
Our areas of focus
An estimated 19 million women in the U.S. have uterine fibroids.
An estimated 7.5 million premenopausal women in the U.S. have endometriosis.
Approximately 3 million men alive today in the U.S. have been diagnosed with prostate cancer.
Myovant is developing innovative medicines that hold promise to improve people’s lives.
3 Apr 2023
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America
26 Jan 2023
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
26 Oct 2022
Myovant Sciences Q2 2022 Earnings Conference Call
13 Sep 2022
Baird 2022 Global Healthcare Conference
8 Aug 2022
MYFEMBREE FDA sNDA Approval Conference Call
27 Jul 2022
Myovant Sciences Q1 2022 Earnings Conference Call
30 Jun 2022
Myovant Statement: U.S. Supreme Court Ruling in Dobbs v. Jackson Women’s Health Organization
You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.